Eric T Wong

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1011129/publications.pdf

Version: 2024-02-01

96 papers	7,917 citations	136950 32 h-index	69250 77 g-index
99 all docs	99 docs citations	99 times ranked	9280 citing authors

#	Article	IF	Citations
1	A pancancer analysis of impact of MDM2/MDM4 on immune checkpoint blockade (ICB).. Journal of Clinical Oncology, 2022, 40, 2630-2630.	1.6	2
2	Final data from the phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2037-2037.	1.6	3
3	Rapid Progressive Glioblastoma despite Radiation in a Patient with Myelodysplastic Syndrome. Case Reports in Oncology, 2021, 14, 424-429.	0.7	0
4	Parkinsonism reversed from treatment of pineal non-germinomatous germ cell tumor. , 2021, 12, 237.		0
5	Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. Frontiers in Oncology, 2021, 11, 679702.	2.8	8
6	Tumor Treating Fields for Ovarian Carcinoma: A Modeling Study. Advances in Radiation Oncology, 2021, 6, 100716.	1.2	4
7	Tumor treating fields in neuro-oncology: integration of alternating electric fields therapy into promising treatment strategies. Chinese Clinical Oncology, 2020, 9, 204-204.	1.2	14
8	Finite element analysis of Tumor Treating Fields in a patient with posterior fossa glioblastoma. Journal of Neuro-Oncology, 2020, 147, 125-133.	2.9	14
9	Dexamethasoneâ€"Friend or Foe for Patients With Glioblastoma?. JAMA Neurology, 2019, 76, 247.	9.0	18
10	Nucleolin Is a Functional Binding Protein for Salinomycin in Neuroblastoma Stem Cells. Journal of the American Chemical Society, 2019, 141, 3613-3622.	13.7	35
11	Quantitative ultrasound of muscle can detect corticosteroid effects. Clinical Neurophysiology, 2019, 130, 1460-1464.	1.5	6
12	The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma. Journal of Visualized Experiments, 2019, , .	0.3	9
13	SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.. Journal of Clinical Oncology, 2019, 37, 2016-2016.	1.6	14
14	Insights from Computer Modeling: Analysis of Physical Characteristics of Glioblastoma in Patients Treated with Tumor-Treating Fields. , 2019, , 155-161.		2
15	Tubulin's response to external electric fields by molecular dynamics simulations. PLoS ONE, 2018, 13, e0202141.	2.5	20
16	Identification of a panel of genes as a prognostic biomarker for glioblastoma. EBioMedicine, 2018, 37, 68-77.	6.1	46
17	Growth Factor Signaling Pathways and Targeted Therapy. , 2018, , 305-322.		0
18	Everolimus shortens survival of newly diagnosed glioblastoma patients. Journal of Neuro-Oncology, 2018, 140, 179-180.	2.9	0

#	Article	IF	Citations
19	Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2018, 140, 317-328.	2.9	107
20	The ESCRT-III Protein CHMP1A Mediates Secretion of Sonic Hedgehog on a Distinctive Subtype of Extracellular Vesicles. Cell Reports, 2018, 24, 973-986.e8.	6.4	79
21	Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality. Progress in Neurological Surgery, 2018, 32, 180-195.	1.3	13
22	Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2015-2015.	1.6	9
23	Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2041-2041.	1.6	3
24	Analysis of physical characteristics of Tumor Treating Fields for human glioblastoma. Cancer Medicine, 2017, 6, 1286-1300.	2.8	33
25	End-to-end workflow for finite element analysis of tumor treating fields in glioblastomas. Physics in Medicine and Biology, 2017, 62, 8264-8282.	3.0	10
26	Skin toxicities associated with tumor treating fields: case based review. Journal of Neuro-Oncology, 2017, 135, 593-599.	2.9	19
27	Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. BMC Cancer, 2016, 16, 914.	2.6	18
28	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro-Oncology, 2016, 18, 849-854.	1.2	45
29	TTFields Therapy. , 2016, , 243-256.		2
30	Computer Simulation of Tumor Treating Fields. , 2016, , 41-54.		0
31	Response Pattern and Modeling of Tumor Treating Fields. , 2016, , 55-65.		0
32	Clinical Efficacy of Tumor Treating Fields for Recurrent Glioblastoma. , 2016, , 67-77.		0
33	Tumor Treating Fields Therapy for Newly Diagnosed Glioblastoma. , 2016, , 93-102.		0
34	Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs. Journal of Visualized Experiments, 2016, , .	0.3	9
35	Neurological presentations of intravascular lymphoma (IVL): meta-analysis of 654 patients. BMC Neurology, 2016, 16, 9.	1.8	73
36	An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma. Current Neurology and Neuroscience Reports, 2016, 16, 8.	4.2	54

#	Article	IF	Citations
37	Tumor-Treating Electric Fields for Glioblastoma. , 2016, , 213-224.		1
38	Computed modeling of alternating electric fields therapy for recurrent glioblastoma. Cancer Medicine, 2015, 4, 1697-1699.	2.8	23
39	Response to: Comment on â€˜Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastomaâ€™. British Journal of Cancer, 2015, 113, 1633-1634.	6.4	3
40	Corrigendum to â€œPost Hoc Analyses of Intention-to-Treat Population in Phase III Comparison of NovoTTF-100Aâ„¢ System Versus Best Physicianâ€™s Choice Chemotherapyâ€™â€™ [Seminars in Oncology, Vol 41, No 5,Suppl 6, October 2014, pp S25-S34]. Seminars in Oncology, 2015, 42, e56-e66.	2.2	1
41	Corrigendum to â€œResponse Patterns of Recurrent Glioblastomas Treated With Tumor-Treating Fieldsâ€• Seminars in Oncology, Vol 41,No 5, Suppl 6, October 2014, pp S14-S24. Seminars in Oncology, 2015, 42, e44-e55.	2.2	0
42	Dosimetric analysis of the alopecia preventing effect of hippocampus sparing whole brain radiation therapy. Radiation Oncology, 2015, 10, 245.	2.7	14
43	Tumor Treating Fields Perturb the Localization of Septins and Cause Aberrant Mitotic Exit. PLoS ONE, 2015, 10, e0125269.	2.5	154
44	Stereotactic Radiosurgery for Renal Cancer Brain Metastasis: Prognostic Factors and the Role of Whole-Brain Radiation and Surgical Resection. Journal of Oncology, 2015, 2015, 1-13.	1.3	23
45	Clinical benefit in recurrent glioblastoma from adjuvant Novo TTF â€100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation. Cancer Medicine, 2015, 4, 383-391.	2.8	27
46	Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers. Lung Cancer, 2015, 88, 108-111.	2.0	369
47	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clinical Cancer Research, 2015, 21, 3610-3618.	7.0	79
48	Tumor treating fields therapy device for glioblastoma: physics and clinical practice considerations. Expert Review of Medical Devices, 2015, 12, 717-726.	2.8	18
49	An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas. Current Treatment Options in Oncology, 2015, 16, 40.	3.0	24
50	Survival benefit of tumor treating fields plus stereotactic radiosurgery for recurrent malignant gliomas.. Journal of Clinical Oncology, 2015, 33, e13036-e13036.	1.6	2
51	A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. Oncotarget, 2015, 6, 2709-2724.	1.8	24
52	Stereotactic radiosurgery for brain metastases from malignant melanoma. , 2015, 6, 355.		24
53	Post Hoc Analyses of Intention-to-Treat Population in Phase III Comparison of NovoTTF-100Aâ„¢ System Versus Best Physicianâ€™s Choice Chemotherapy. Seminars in Oncology, 2014, 41, S25-S34.	2.2	80
54	Resolution of Cystic Enhancement to Add-On Tumor Treating Electric Fields for Recurrent Glioblastoma after Incomplete Response to Bevacizumab. Case Reports in Neurology, 2014, 6, 109-115.	0.7	7

#	Article	IF	Citations
55	Response assessment of NovoTTFâ€100A versus best physician's choice chemotherapy in recurrent glioblastoma. Cancer Medicine, 2014, 3, 592-602.	2.8	53
56	Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid. Melanoma Research, 2014, 24, 120-130.	1.2	30
57	Response Patterns of Recurrent Glioblastomas Treated With Tumor-Treating Fields. Seminars in Oncology, 2014, 41, S14-S24.	2.2	59
58	The natural history of intravascular lymphomatosis. Cancer Medicine, 2014, 3, 1010-1024.	2.8	70
59	Characterization and Management of Dermatologic Adverse Events With the NovoTTF-100A System, a Novel Anti-mitotic Electric Field Device for the Treatment of Recurrent Glioblastoma. Seminars in Oncology, 2014, 41, S1-S14.	2.2	79
60	Contributors to contrast between glioma and brain tissue in chemical exchange saturation transfer sensitive imaging at 3Tesla. NeuroImage, 2014, 99, 256-268.	4.2	70
61	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.. Journal of Clinical Oncology, 2014, 32, 2004-2004.	1.6	4
62	NovoTTF-100A alternating electric fields therapy for recurrent glioblastoma: An analysis of patient registry data.. Journal of Clinical Oncology, 2014, 32, e13033-e13033.	1.6	1
63	T-cell primary central nervous system lymphoma: A systematic literature analysis.. Journal of Clinical Oncology, 2014, 32, e13034-e13034.	1.6	0
64	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma: Final results.. Journal of Clinical Oncology, 2014, 32, 2027-2027.	1.6	0
65	Primary spinal cord glioblastoma: A systematic review.. Journal of Clinical Oncology, 2014, 32, e13035-e13035.	1.6	0
66	Metabolomics of Human Cerebrospinal Fluid Identifies Signatures of Malignant Glioma. Molecular and Cellular Proteomics, 2012, 11, M111.014688.	3.8	89
67	Reply to Dr. Beauchesne. Journal of Neuro-Oncology, 2012, 109, 595-595.	2.9	0
68	Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Review of Neurotherapeutics, 2012, 12, 1207-1215.	2.8	69
69	NovoTTF-100A versus physicianâ€™s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. European Journal of Cancer, 2012, 48, 2192-2202.	2.8	661
70	Superior semicircular canal dehiscence in East Asian women with osteoporosis. BMC Ear, Nose and Throat Disorders, 2012, 12, 8.	2.6	20
71	NovoTTF-100A: a new treatment modality for recurrent glioblastoma. Expert Review of Neurotherapeutics, 2012, 12, 895-899.	2.8	66
72	Noninvasive Application of Alternating Electric Fields in Glioblastoma: A Fourth Cancer Treatment Modality. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 126-131.	3.8	39

#	Article	IF	Citations
73	Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 403-407.	4.9	118
74	The natural history of extracranial metastasis from glioblastoma multiforme. Journal of Neuro-Oncology, 2011, 105, 261-273.	2.9	168
75	Treatment advances for glioblastoma. Expert Review of Neurotherapeutics, 2011, 11, 1343-1345.	2.8	5
76	Rare Phenomenon of Extracranial Metastasis of Glioblastoma. Journal of Clinical Oncology, 2011, 29, 4594-4595.	1.6	31
77	Angiogenesis and Brain Tumors. , 2011, , 1151-1171.		1
78	Phase I Study of Vandetanib With Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2010, 78, 85-90.	0.8	76
79	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology, 2010, 28, 1963-1972.	1.6	3,222
80	Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas. Cerebrospinal Fluid Research, 2008, 5, 1.	0.5	36
81	Bevacizumab Reverses Cerebral Radiation Necrosis. Journal of Clinical Oncology, 2008, 26, 5649-5650.	1.6	95
82	Antiangiogenesis Treatment for Glioblastoma Multiforme: Challenges and Opportunities. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 515-522.	4.9	67
83	Taming Glioblastoma: Targeting Angiogenesis. Journal of Clinical Oncology, 2007, 25, 4705-4706.	1.6	38
84	Matrix Metalloproteaseâ€“9 in Cerebrospinal Fluid Correlates with Disease Activity in Lymphomatous Meningitis. Clinical Lymphoma and Myeloma, 2007, 7, 305-308.	1.4	4
85	Cyberknife Radiosurgery for Basal Skull Plasmacytoma. Journal of Neuroimaging, 2006, 16, 361-363.	2.0	17
86	Tumor growth, invasion, and angiogenesis in malignant gliomas. Journal of Neuro-Oncology, 2006, 77, 295-296.	2.9	13
87	Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology, 2005, 64, 934-934.	1.1	9
88	Management of Central Nervous System Lymphomas Using Monoclonal Antibodies: Challenges and Opportunities. Clinical Cancer Research, 2005, 11, 7151s-7157s.	7.0	21
89	Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm. Expert Opinion on Pharmacotherapy, 2005, 6, 1107-1114.	1.8	7
90	The Role of Topotecan in the Treatment of Brain Metastases. Oncologist, 2004, 9, 68-79.	3.7	101

#	Article	IF	Citations
91	Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer, 2004, 101, 139-145.	4.1	131
92	Unusual Locations for Lymphomas. Journal of Clinical Oncology, 2001, 19, 2960-2963.	1.6	6
93	Meningeal Carcinomatosis in Lung Cancer. Journal of Clinical Oncology, 2000, 18, 2926-2927.	1.6	10
94	Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials. Journal of Clinical Oncology, 1999, 17, 2572-2572.	1.6	850
95	Response and progression in recurrent malignant glioma. Neuro-Oncology, 1999, 1, 282-288.	1.2	34
96	Guidelines for Burr Hole Surgery in Combination With Tumor Treating Fields for Glioblastoma: A Computational Study on Dose Optimization and Array Layout Planning. Frontiers in Human Neuroscience, 0, 16, .	2.0	0